BMS, Mounjaro and HRT: what changes when you're on both

The situation: you're managing menopause and weight at the same time

You've been living with menopausal symptoms for long enough to know they don't stay in neat categories. Hot flushes affect sleep. Poor sleep affects appetite. Weight gain around the abdomen is common in perimenopause and beyond, and it isn't simply about eating more. You might be on HRT that's working well, or you might be on a waiting list for the right formulation. Either way, Mounjaro has come up as an option (perhaps your GP mentioned it, or you read about it) and now you need to know whether the two medicines play nicely together.

The BMS position, consistent with NHS England's clinical guidance, is that the form your HRT takes really does matter when GLP-1 and dual-agonist medicines like tirzepatide are involved. This isn't theoretical. Mounjaro slows the rate at which your stomach empties, and that has downstream effects on anything absorbed through the gut wall, including oral hormone tablets. Understanding that mechanism is the first step.

Why oral HRT and Mounjaro don't always mix well

Tirzepatide is a dual GIP and GLP-1 receptor agonist. One of the ways it reduces appetite is by slowing gastric emptying, food (and everything else in the stomach) moves into the small intestine more slowly than usual. For most purposes that's the whole point. But it creates a timing and absorption problem for oral medicines that rely on predictable gut transit.

Oral oestrogen and oral progesterone tablets sit in this category. If gastric emptying is delayed, the hormone may spend longer in an environment where it isn't absorbed efficiently, and plasma levels can vary in ways they wouldn't if your gut were working at its usual pace. NHS England's guidance on combining Mounjaro and HRT specifically flags oral preparations as the ones to reconsider, and recommends that prescribers discuss switching to transdermal delivery.

This is why the BMS advice aligns with what clinicians at services like ours hear regularly: if a patient is starting tirzepatide and is on oral HRT, the first conversation isn't about stopping HRT, it's about whether the route can change. Patches applied to the thigh or lower abdomen, or a gel rubbed into the inner arm each morning before everything else, deliver oestrogen through the skin. The gut is not involved at all. You can read more about the specifics on our tirzepatide and HRT page.

Transdermal HRT: what it means day to day

Switching to a patch or gel isn't disruptive for most people. Patches typically last three to four days and can be stuck to the lower abdomen, buttocks or thigh, kept away from the waistband and out of water for the first few minutes after application. Gels are applied once daily; many people slot it in while the kettle boils, before coffee, before anything else has touched the skin.

The clinical upside is straightforward: transdermal oestrogen also carries a lower associated risk of venous thromboembolism than oral oestrogen, a point the BMS has emphasised independently of the tirzepatide question. So for some women, moving to a patch or gel while starting Mounjaro is a change that makes sense on more than one count.

Progestogen delivery is slightly more variable, some women use a hormonal IUS (Mirena) for the progestogen component, which sidesteps the absorption question completely. Others use a body-identical oral micronised progesterone at night, and whether that formulation is affected by Mounjaro's gastric-emptying effect is something to discuss with whoever manages your HRT. The effect of Mounjaro on HRT-related bleeding patterns is a separate but related question your prescriber can address.

For a broader look at how Mounjaro works as a weight-management treatment, including clinical trial evidence and eligibility, our BMS and Mounjaro overview covers the fuller picture. Cost is often a question at this stage too, our Mounjaro pricing page sets out what to expect from private treatment.

What to tell your prescriber, and what they'll ask you

Any clinician reviewing you for Mounjaro should ask about your current medicines. HRT is not a contraindication to tirzepatide, but it changes what needs to be discussed. If you're on oral HRT, the conversation about switching to transdermal should happen before you start, not after you notice your HRT feels less effective.

Equally, if you're already on Mounjaro and your GP wants to start or adjust HRT, tell them which dose you're on. The gastric-emptying effect is dose-related to some degree, so the picture at 2.5mg differs from the picture at 10mg. Our clinical team reviews every consultation individually (a prescriber reads your answers, not software) and that review includes checking for interactions with existing medicines. NHS England's guidance on weight-management injections sets out the HRT and contraception considerations clearly, and it's worth reading if you want the official wording before your appointment.

Both Mounjaro and HRT are prescription-only medicines. You can explore whether tirzepatide fits your situation by speaking to our prescribers through a free consultation, no obligation, no automatic approval, just a proper clinical look at your circumstances.